🇺🇸 FDA
Pipeline program

Norovirus Bivalent Vaccine

LV03-105

Phase 2 mab completed

Quick answer

Norovirus Bivalent Vaccine for Prevention From Norovirus Infection is a Phase 2 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
Prevention From Norovirus Infection
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials